POST Online Media Lite Edition


NEWLY REPORTED COVID-19 CASES (11.19.2021, 4:50pm CEST, WHO):   India 11,106    Brazil 11,977    United Kingdom 46,858    Russia 37,156    Turkey 22,234    France 19,840    Argentina 1,553    Germany 52,970    Spain 3,932    Columbia 2,257    Italy 10,645    Mexico 3,836    Ukraine 20,050    Poland 23,242    Philippines 1,297    Malaysia 6,380    Netherlands 23,680    Peru 1,370    Thailand 6,855    Czechia 13,374    Canada 2,448    Romania 3,076    Chile 2,611    Serbia 3,219    Sweden 1,210    Portugal 2,398    Vietnam 10,223    Kazakhstan 1,272    Austria 14,212    Hungary 11,289    Greece 7,276    Georgia 4,278    Bulgaria 2,785    Belarus 1,844    Slovakia 7,418    Azerbaijan 2,124    Croatia 7,270    Bolivia 1,119    Ireland 4,646    Lithuania 1,847    Denmark 4,013    South Korea 3,034    Slovenia 3,662    Latvia 1,221    Laos 1,401    China 31    New Zealand 200    Australia 1,302   

FDA: Salmonella resistance increased

Christian Fernsby |
The US Food and Drug Administration (FDA), in cooperation with the Centers for Disease Control and Prevention (CDC) and the US Department of Agriculture’s Food Safety and Inspection Service (USDA-FSIS), its partners in the National Antimicrobial Resistance Monitoring System (NARMS), released the 2016-2017 NARMS Integrated Summary.

Article continues below


The new streamlined format will replace the annual NARMS Integrated Reports and enable NARMS partners to issue more timely public updates in the future.

The NARMS Integrated Summary draws upon antimicrobial resistance patterns in bacteria isolated from humans (by CDC), raw retail meats (by FDA), and animals at slaughter (by USDA) to provide key takeaways on rates of resistance to the most important antimicrobial agents.

NARMS continues to share its data in interactive displays that allow users to access the full data set and explore the dynamics of antimicrobial resistance and the genes involved.

This 2016-2017 Integrated Summary is the first time NARMS has included data on animal pathogens from a pilot study with FDA’s Veterinary Laboratory Investigation and Response Network (Vet-LIRN).

In addition, this summary is the first time that NARMS will provide genomic information for Campylobacter and E. coli retail meat and food animal isolates.

Up to this point, this information was only available for Salmonella.

Salmonella resistance to third-generation cephalosporins, fluoroquinolones, or azithromycin has increased.

This is concerning as these drugs are considered first-line therapies to treat complicated infectious diarrhoea in humans.

The rise in Salmonella resistance to these drugs means that treatment with them way not always work.

No resistance to carbapenems was observed among Salmonella isolates from humans, retail meats, and animals.

This is important as carbapenems are typically reserved to treat suspected multi-drug resistant infectious diarrhoea.

In the U.S., carbapenems are not used in food animal production, however due to

heir importance in human health, they are monitored by NARMS. Rates of macrolide and fluoroquinolone resistance remain relatively unchanged in Campylobacter jejuni isolated from humans and chickens, and in Campylobacter coli isolated from cattle and swine.

While it is positive that these rates of resistance did not increase, the rates of macrolide resistance in Campylobacter isolated from swine and fluoroquinolone resistance in Campylobacter isolated from cattle warrant further monitoring.

What to read next

FDA seeks permanent injunctions against two stem cell clinics
50-year-old bacteria could be alternative treatment option for cancer
Scientists find link between increases in local temperature and antibiotic resistance